Capricor Therapeutics reported positive topline results from its pivotal Phase III HOPE‑3 trial of deramiocel in Duchenne muscular dystrophy (DMD), meeting its primary functional endpoint and a key cardiac secondary endpoint. The randomized study showed statistically significant improvements in upper‑limb performance and left ventricular ejection fraction, outcomes that the company says address prior FDA concerns after a previous rejection. Investors responded immediately, sending shares sharply higher. Deramiocel is a cell/exosome‑based therapy developed to reduce inflammation, fibrosis and cardiac decline in DMD; the HOPE‑3 readout sets the stage for a regulatory resubmission and further meetings with CDER.